{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T02:50:57Z","timestamp":1781923857742,"version":"3.54.5"},"reference-count":34,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To evaluate the functional and structural outcomes in patients with neovascular age-related macular degeneration (nAMD) switched from ranibizumab or aflibercept to bevacizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study included 197 eyes of 192 patients (mean age 83\u2009\u00b1\u20096 years; 38% male). Patients previously treated with ranibizumab (n\u2009=\u200979) or aflibercept (n\u2009=\u2009118) were transitioned to bevacizumab. Best-corrected visual acuity (BCVA) was recorded with ETDRS charts and converted to logMAR. Spectralis SD-OCT was used to evaluate intraretinal and subretinal fluid, presence of retinal pigment epithelium detachment (PED), PED height and central retinal thickness (CRT) at baseline and after 6 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Mean BCVA decreased from 0.4\u2009\u00b1\u20090.3 to 0.5\u2009\u00b1\u20090.4 logMAR (p\u2009=\u20090.048). The proportion of eyes with intraretinal or subretinal fluid rose from 27% to 69% (p\u2009=\u20090.017). Subgroup analysis indicated greater functional and structural worsening in younger patients and in those switched from aflibercept. Mean PED height showed a non-significant increase from 163\u2009\u00b1\u200994 to 166\u2009\u00b1\u200995\u2005\u00b5m (p\u2009=\u20090.091), mean PED height showed a non-significant increase from 163\u2009\u00b1\u200994 to 166\u2009\u00b1\u200995\u2005\u00b5m (p\u2009=\u20090.091). In contrast, mean CRT increased substantially from 294\u2009\u00b1\u200930\u2005\u00b5m at baseline to 310\u2009\u00b1\u200926 at 6 months (p (p\u2009&lt;\u20091\u2009\u00d7\u200910\n                      <jats:sup>\u22127<\/jats:sup>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Switching from ranibizumab or aflibercept to bevacizumab may lead to reduced visual function and an increase in structural-OCT markers of disease activity, including greater intraretinal\/subretinal fluid, CRT and worsening PED features, particularly in younger individuals and in eyes previously treated with aflibercept.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/11206721251409237","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T18:08:44Z","timestamp":1766426924000},"page":"972-979","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Functional and Structural Impact of Switching to Bevacizumab in neovascular-AMD Patients Treated with Aflibercept or Ranibizumab"],"prefix":"10.1177","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0377-7491","authenticated-orcid":false,"given":"Alessio","family":"Muzi","sequence":"first","affiliation":[{"name":"Humanitas-Gradenigo Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Gregori","sequence":"additional","affiliation":[{"name":"Polytechnic University of Marche"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Mangoni","sequence":"additional","affiliation":[{"name":"Polytechnic University of Marche"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Mogetta","sequence":"additional","affiliation":[{"name":"Polytechnic University of Marche"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8932-5343","authenticated-orcid":false,"given":"Jay","family":"Chhablani","sequence":"additional","affiliation":[{"name":"University of Pittsburgh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Fruttini","sequence":"additional","affiliation":[{"name":"University of Perugia, S. Maria della Misericordia Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2410-9775","authenticated-orcid":false,"given":"Tito","family":"Fiore","sequence":"additional","affiliation":[{"name":"University of Perugia, S. Maria della Misericordia Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5156-5314","authenticated-orcid":false,"given":"Clara","family":"Rizzo","sequence":"additional","affiliation":[{"name":"Drug Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesare","family":"Mariotti","sequence":"additional","affiliation":[{"name":"Polytechnic University of Marche"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6817-2488","authenticated-orcid":false,"given":"Marco","family":"Lupidi","sequence":"additional","affiliation":[{"name":"Polytechnic University of Marche"},{"name":"Fondazione Italiana Macula ETS, Di.N.O.G.Mi., University Eye Clinic, Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,12,22]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(13)70145-1"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.03.053"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062655"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054481"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-019-04569-8"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.09.006"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-021-00499-2"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-016-0391-4"},{"key":"e_1_3_4_10_2","first-page":"1857","article-title":"Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review","volume":"10","author":"Yang S","year":"2016","unstructured":"Yang S, Zhao J, Sun X. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. Drug Des Devel Ther. 2016; 10: 1857\u201367.","journal-title":"Drug Des Devel Ther"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e318134eecd"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjo.2012.01.003"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2011.204685"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2013.03.030"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2014.101"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2013-303344"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.08.035"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2013.02.017"},{"key":"e_1_3_4_19_2","unstructured":"Nota 98 per la prescrizione e somministrazione intravitreale di anti-VEGF nella AMD e DME [Internet]. [cited 2025 Jan 5];Available from: https:\/\/www.aifa.gov.it\/-\/nota-98-per-la-prescrizione-e-somministrazione-intravitreale-di-anti-vegf-nella-amd-e-dme"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1177\/1120672119883602"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1159\/000380832"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032691"},{"key":"e_1_3_4_23_2","article-title":"The Efficacy, Safety, and Efficiency of the Off-Label Use of Bevacizumab in Patients Diagnosed With Age-Related Macular Degeneration: Protocol for a Systematic Review and Meta-Analysis","volume":"12","author":"Estarreja J","year":"2023","unstructured":"Estarreja J, Mendes P, Silva C, Camacho P, Mateus V. The Efficacy, Safety, and Efficiency of the Off-Label Use of Bevacizumab in Patients Diagnosed With Age-Related Macular Degeneration: Protocol for a Systematic Review and Meta-Analysis. JMIR Res Protoc. 2023; 12: e38658.","journal-title":"JMIR Res Protoc"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.3129\/i10-095"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/7940297"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00063-1"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2024.02.014"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.09.018"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.08.023"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.07.041"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-020-04893-4"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-011-9249-6"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.5301\/ejo.5000268"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1159\/000363422"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2415-14-159"}],"container-title":["European Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11206721251409237","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/11206721251409237","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11206721251409237","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T02:01:48Z","timestamp":1781920908000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/11206721251409237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1177\/11206721251409237"],"URL":"https:\/\/doi.org\/10.1177\/11206721251409237","relation":{},"ISSN":["1120-6721","1724-6016"],"issn-type":[{"value":"1120-6721","type":"print"},{"value":"1724-6016","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,22]]}}}